StockData
MaxCyte, Inc. logo

MaxCyte, Inc. (MXCT) stock

MXCTNasdaqServices-Commercial Physical & Biological ResearchFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 10, 2026Score 11/3065% below fair value
$1.10−0.03 (-2.65%)

Close on Nov 11, 2026Market cap $113.53MP/E –Yield –

Earnings

MaxCyte's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Mar 23, 2027
Q4 FY2026 · estimated, after the close
Revenue, Q2 FY2026
$7.30M
-14.1% on a year earlier
EPS, Q2 FY2026
–
Latest guidance
Raised
Oct 14, 2026 · 1 item

Quarterly results

Revenue and earnings per share from each of MaxCyte's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q4 FY2026ended Dec 31, 2026Mar 23, 2027Expected––––
Q3 FY2026ended Sep 30, 2026Nov 10, 2026before the open–––Release
Q2 FY2026ended Jun 30, 2026Aug 12, 2026after the close$7.30M-14.1%–Release
Q1 FY2026ended Mar 31, 2026May 12, 2026after the close$9.70M-6.7%–Release
Q4 FY2025ended Dec 31, 2025Mar 24, 2026after the close$7.30M-16.1%–Release
Q3 FY2025ended Sep 30, 2025Nov 12, 2025after the close$6.80M-17.1%–Release
Q2 FY2025ended Jun 30, 2025Aug 6, 2025after the close$8.50M-18.3%–Release
Q1 FY2025ended Mar 31, 2025May 7, 2025after the close$10.40M-8.0%–Release
Q4 FY2024ended Dec 31, 2024Mar 11, 2025after the close$8.70M-44.6%–Release
Q3 FY2024ended Sep 30, 2024Nov 6, 2024after the close$8.20M+2.5%–Release
Q2 FY2024ended Jun 30, 2024Aug 6, 2024after the close$10.40M+15.6%–Release
Q1 FY2024ended Mar 31, 2024May 7, 2024after the close$11.30M+31.4%–Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

MaxCyte's latest outlook for periods it has not reported yet, compared with what it said before

MetricPeriodGuidanceBeforeChangeGiven
Full year revenueFY2026$34.00M$30.00M – $32.00MRaisedOct 14, 2026
Full year revenueFY2026$30.00M – $32.00M$30.00M – $32.00MReaffirmedAug 12, 2026
Core revenueFY2026$25.00M – $27.00M–NewMay 12, 2026
SPL Program-related revenueFY2026$5.00M–LoweredMay 12, 2026
total cash, cash equivalents and investmentsFY2026$130.50M$136.00MLoweredAug 12, 2026

Guidance vs results

The last range MaxCyte gave before each report, against the figure it then reported. Full years add up the four quarters.

PeriodMetricGuidanceActualResult
FY2025Revenue$5.00M$33.00MΣ4QAbove range

Guidance history

Every forecast MaxCyte put in an earnings release, newest first

GivenMetricPeriodGuidanceChange
Oct 14, 2026Full year revenueFY2026$34.00MRaised
Aug 12, 2026total cash, cash equivalents and investmentsFY2026$130.50MLowered
Aug 12, 2026Full year revenueFY2026$30.00M – $32.00MReaffirmed
Aug 12, 2026Core revenueFY2026$25.00M – $27.00MLowered
Aug 12, 2026SPL Program-related revenueFY2026$5.00MLowered
May 12, 2026Core revenueFY2026$25.00M – $27.00MNew
May 12, 2026SPL Program-related revenueFY2026$5.00MLowered
May 12, 2026total cash, cash equivalents and investmentsFY2026$136.00MRaised
May 12, 2026Full year revenueFY2026$30.00M – $32.00MNew
Mar 24, 2026Full year revenueFY2026$30.00M – $32.00MNew
Nov 12, 2025total cash, cash equivalents and investmentsFY2025$152.00M – $155.00MLowered
Nov 12, 2025SPL Program-related revenueFY2025$5.00MReaffirmed
Nov 5, 2025total cash, cash equivalents and investmentsFY2025$152.00M – $155.00MNew
Nov 5, 2025SPL Program-related revenueFY2025$5.00MNew
Aug 6, 2025SPL Program-related revenueFY2025$5.00MReaffirmed
May 7, 2025total cash, cash equivalents and investmentsFY2025$160.00MReaffirmed
May 7, 2025Core revenueFY2025+8% – +15%Reaffirmed
May 7, 2025SPL Program-related revenueFY2025$5.00MReaffirmed
Mar 11, 2025total cash, cash equivalents and investmentsFY2025$160.00MNew
Mar 11, 2025Core revenueFY2025+8% – +15%New

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.

Press releases

Releases MaxCyte filed with the SEC as exhibits to Form 8-K or 6-K

  1. Third Quarter 2026 Financial Results and Updates Full Year 2026 Total Revenue Guidance
    Results
  2. MaxCyte to Acquire Akron Bio,
    Results
  3. are trademarks of MaxCyte, Inc. in the U.S.A.
    Results
  4. MaxCyte Reports Preliminary Third Quarter 2026
    Results
  5. MaxCyte Reports Second Quarter 2026 Financial Results
    Results
  6. are trademarks of MaxCyte, Inc. in the U.S.A.
    Results
  7. MaxCyte Reports First Quarter 2026 Financial Results and Reiterates Full Year 2026 Guidance
    Results
  8. are trademarks of MaxCyte, Inc. in the U.S.A.
    Results
  9. MaxCyte Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Full Year 2026 Guidance
    Results
  10. are trademarks of MaxCyte, Inc. in the U.S.A.
    Results
  11. MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2025 Financial Results
    Results
  12. MaxCyte Reports Third Quarter 2025 Financial Results and Reiterates Full Year 2025 Revenue Guidance
    Results
  13. are registered trademarks of MaxCyte, Inc. in the U.S.A.
    Results
  14. MaxCyte Reports Preliminary Third Quarter 2025 Financial Results and Reiterates Full Year 2025 Revenue Guidance
    Results
  15. MaxCyte Announces Operational Restructuring to Reduce Costs and Accelerate Path to Profitability
    Update

See a number that looks wrong?